Epstein, David M.
Vice Dean
Cancer & Stem Cell Biology
Duke-NUS Graduate Medical School
Singapore
Biography
Prior to joining OSI Oncology, David was a principal founder and Vice President of Archemix Corp (2001-2006). While in this capacity, David facilitated the development of two therapeutic aptamers currently in late-stage clinical development for treating wet and dry macular degeneration. David has 20 years of leadership experience in both the pharmaceutical and biotechnology industries, leading wide-ranging efforts in oncology, ophthalmic and cardiovascular drug discovery. Currently, David provides consulting for early stage biotech enterprises, and is co-Founder of ASET Therapeutics (New York and Basel, Switzerland).
Research Interest
Comprehensive molecular and mechanistic understanding of tumor cell mesenchymalization, using clinical specimens and disease models
Publications
-
Zhao, H., Desai, V., Wang, J., Epstein, D.M., Miglarese, M.A., Buck, E., (2012), “Epithelial-Mesenchymal-Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Tumor Cell Lines,†Molecular Cancer Therapeutics, 11: 503.
-
Wang, M., Sips, P., Khin, E., Rotival, M., Sun, X.M. Rizwan, A., Anindya, A., Sebastian Schafer, S., Yusoff, P., Kaur P.C., Shi J.K., Singh, M., Epstein, D.M., Guan, Y., Hous, K., Mracek, T., Nuskova, H., Mikell, B., Tan, J., Pesce, F., Kolar, F., Bottolo, L., Mancini, M., Hubner, N., Pravenec, M., Petretto, E., MacRae, C., and Cook, S.A., (2016) "Wars2 is a novel determinant of angiogenesis," Nature Communications, 8 July, 7:12061.
